

Table 2. Neutralising activity among CML patients and controls, and among CML patients based on tyrosine kinase inhibitors and duration of treatment.

Inhibition for Omicron BA.1	CML	Controls	P value	Imatinib	Nilotinib	P value	TKI <10 years	TKI ≥10 years	P value
D28**									
≤30%	21 (80.8)	46 (85.2)	0.748	17 (85.0)	3 (60.0)	0.252	7 (77.8)	14 (82.4)	1.000
>30%	5 (19.2)	8 (14.8)		3 (15.0)	2 (40.0)		2 (22.2)	3 (17.6)	
Unadjusted (Exp[B], 95% CI)***	1.369 (0.400 – 4.688)		0.617	3.778 (0.431 – 33.077)		0.230	0.750 (0.101 – 5.576)		0.779
Adjusted (Exp[B], 95% CI)***	1.403 (0.357 – 5.514)		0.627	3.233 (0.344 – 30.372)		0.305	0.975 (0.118 – 8.068)		0.981
M6**									
≤30%	23 (85.2)	39 (90.7)	0.702	18 (85.7)	4 (80.0)	1.000	8 (88.9)	15 (83.3)	1.000
>30%	4 (14.8)	4 (9.3)		3 (14.3)	1 (20.0)		1 (11.1)	3 (16.7)	
Unadjusted (Exp[B], 95% CI)***	1.696 (0.387 – 7.438)		0.484	1.500 (0.122 – 18.441)		0.751	1.600 (0.142 – 18.000)		0.704
Adjusted (Exp[B], 95% CI)***	0.968 (0.154 – 6.083)		0.973	1.690 (0.130 – 22.017)		0.689	1.457 (0.122 – 17.358)		0.766
B3**									
≤30%	6 (31.6)	13 (22.0)	0.539	5 (35.7)	1 (25.0)	1.000	1 (16.7)	5 (38.5)	0.605
>30%	13 (68.4)	46 (78.0)		9 (64.3)	3 (75.0)		5 (83.3)	8 (61.5)	
Unadjusted (Exp[B], 95% CI)***	0.612 (0.195 – 1.927)		0.402	1.667 (0.135 – 20.578)		0.690	0.320 (0.28 – 3.600)		0.356
Adjusted (Exp[B], 95% CI)***	0.606 (0.188 – 1.958)		0.402	1.603 (0.128 – 20.100)		0.715	0.335 (0.029 – 3.829)		0.379
B6**									
≤30%	10 (50.0)	4 (11.1)	0.003*	6 (42.9)	4 (80.0)	0.303	4 (57.1)	6 (46.2)	1.000
>30%	10 (50.0)	32 (88.9)		8 (57.1)	1 (20.0)		3 (42.9)	7 (53.8)	
Unadjusted (Exp[B], 95% CI)***	0.125 (0.032 – 0.487)		0.003*	0.188 (0.016 – 2.137)		0.178	1.556 (0.244 – 9.913)		0.640
Adjusted (Exp[B], 95% CI)***	0.136 (0.034 – 0.538)		0.005*	0.164 (0.013 – 2.088)		0.164	1.630 (0.235 – 11.320)		0.621
B12**									
≤30%	4 (20.0)	5 (14.3)	0.709	2 (14.3)	2 (40.0)	0.272	1 (14.3)	3 (23.1)	1.000
>30%	16 (80.0)	30 (85.7)		12 (85.7)	3 (60.0)		6 (85.7)	10 (76.9)	
Unadjusted (Exp[B], 95% CI)***	0.667 (0.157 – 2.836)		0.583	0.250 (0.024 – 2.577)		0.244	0.556 (0.047 – 6.629)		0.642
Adjusted (Exp[B], 95% CI)***	0.703 (0.163 – 3.034)		0.637	0.245 (0.022 – 2.766)		0.255	0.475 (0.035 – 6.516)		0.475

CI: confidence interval; CML: chronic myeloid leukaemia IQR: interquartile range; TKI: tyrosine kinase inhibitor

* indicates *P* values <0.05.

** Group comparisons were performed using the Chi-square test.

*** Binary logistic regression analyses were conducted with and without adjustment for age. Control group, imatinib treatment, and TKI duration <10 years were used as reference categories.